)
Corvus Pharmaceuticals (CRVS) investor relations material
Corvus Pharmaceuticals Proxy filing summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Voting matters and shareholder proposals
Election of two Class I Directors for terms expiring at the 2029 annual meeting is proposed, with board recommendation to vote FOR.
Ratification of PricewaterhouseCoopers LLP as independent registered public accounting firm for fiscal year ending December 31, 2026, recommended FOR.
Advisory vote to approve compensation of named executive officers, with board recommendation to vote FOR.
Board of directors and corporate governance
Board recommends the election of two director nominees to serve until the 2029 annual meeting.
Executive compensation and say-on-pay
Shareholders are asked to approve, on a non-binding basis, the compensation of named executive officers.
- Virtual meeting to elect directors, ratify auditor, and approve executive pay, with focus on governance.CRVS
Proxy filing24 Apr 2026 - Soquelitinib showed robust efficacy, safety, and immune modulation in atopic dermatitis Phase 1.CRVS
Study result12 Apr 2026 - Strong clinical and financial momentum with soquelitinib, supporting pipeline expansion and durability.CRVS
Q4 202512 Mar 2026 - Soquelitinib shows robust efficacy and safety in AD, targeting broad immune disease markets.CRVS
Corporate presentation12 Mar 2026 - Soquelitinib shows robust efficacy and safety in atopic dermatitis, targeting a major unmet need.CRVS
Corporate presentation26 Feb 2026 - Soquelitinib shows durable efficacy in AD and advances toward pivotal trials in major immune diseases.CRVS
Oppenheimer 36th Annual Healthcare Life Sciences Conference26 Feb 2026 - Soquelitinib advances in PTCL and atopic dermatitis, with $47.3M cash runway into late 2025.CRVS
Q2 20242 Feb 2026 - Lead ITK inhibitor shows strong efficacy in lymphoma, with broad expansion and solid financial runway.CRVS
Jefferies 2024 Global Healthcare Conference1 Feb 2026 - Soquelitinib advances in phase III for T-cell lymphoma, showing strong efficacy and broad potential.CRVS
H.C. Wainwright 26th Annual Global Investment Conference 202421 Jan 2026
Next Corvus Pharmaceuticals earnings date
Next Corvus Pharmaceuticals earnings date
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
)
)
Frequently asked questions
Explore our global coverage